Clenpiq Shortage: What Providers and Prescribers Need to Know in 2026

Clenpiq Availability: A Provider Briefing for 2026

Clenpiq (Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid) has become a preferred bowel preparation for many gastroenterology practices and their patients. Its low-volume, ready-to-drink format leads to high completion rates and strong patient satisfaction — 98% of patients in clinical trials reported willingness to repeat the prep.

However, providers across the country are hearing a familiar complaint from patients: "My pharmacy doesn't have Clenpiq." This briefing covers what you need to know about Clenpiq's supply status, prescribing implications, and practical strategies for ensuring your patients are adequately prepared for their procedures.

Current Supply Timeline

Clenpiq is manufactured exclusively by Ferring Pharmaceuticals. As of early 2026, it is not listed on the FDA Drug Shortage Database, meaning no formal supply disruption has been reported by the manufacturer.

However, the practical reality at the pharmacy level tells a different story. Clenpiq remains a brand-only product with no generic equivalent. Many retail pharmacies — particularly large chains — do not routinely stock it due to its intermittent demand profile. This creates persistent availability gaps that mimic the effects of a shortage, even when manufacturer supply is stable.

This pattern has been consistent since Clenpiq's initial FDA approval in 2012. As a single-source, procedure-specific medication, it has always required more proactive prescribing and dispensing workflows than daily-use medications.

Prescribing Implications

The availability challenges around Clenpiq have several implications for prescribers:

Timing of Prescriptions

Prescribing Clenpiq at the time of colonoscopy scheduling — rather than a few days before the procedure — gives pharmacies adequate time to order and stock the medication. A lead time of 7–14 days significantly reduces the risk of patients arriving at their appointment without having completed an adequate prep.

Pharmacy Selection Guidance

Consider advising patients to check availability before filling their prescription. Independent pharmacies and specialty pharmacies are often more reliable sources for procedure-specific medications like Clenpiq. Tools like Medfinder for Providers can help your practice identify pharmacies with current stock.

Alternative Prep Protocols

Having a backup bowel prep protocol is essential. When Clenpiq is unavailable, the most commonly substituted alternatives include:

• Suprep Bowel Prep Kit (Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate) — widely available, generic versions accessible at $30–$80
• Plenvu (PEG-based, low-volume) — brand-only, approximately $200–$350
• Suflave (PEG-based, low-volume) — newer option, brand-only, approximately $200–$300
• MoviPrep (PEG-based) — available in generic form at $20–$60, moderate volume
• GoLYTELY/NuLYTELY (PEG 3350 and electrolytes) — high-volume but inexpensive and universally available

Each alternative has different contraindication profiles. For patients with renal impairment, cardiac history, or electrolyte disorders, carefully evaluate the substitute prep's safety profile. For a patient-facing comparison, see: Alternatives to Clenpiq.

Availability Picture

The availability of Clenpiq varies significantly by region and pharmacy type:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Inconsistent stocking. Many locations do not carry Clenpiq routinely and require special orders from their wholesaler.
• Independent pharmacies: More likely to accommodate special orders with shorter turnaround times. Some independent pharmacies near GI practices proactively stock bowel preps.
• Hospital outpatient pharmacies: May stock Clenpiq if the affiliated GI department has it on their formulary.
• Specialty pharmacies: Most reliable for procedure-related medications but may not be convenient for all patients.

Cost and Access Considerations

Understanding the cost landscape helps when discussing options with patients:

• Clenpiq retail price: approximately $252 without insurance
• Insurance coverage: most commercial and Medicare Part D plans cover Clenpiq with copays typically $20–$75
• Manufacturer coupon: Ferring offers a savings card — commercially insured patients may pay as little as $50; cash patients get $40 off (available at clenpiq.com)
• No patient assistance program: Ferring does not currently offer a formal PAP for Clenpiq, which may affect uninsured or underinsured patients

For patients where cost is a barrier, generic Suprep ($30–$80) or generic MoviPrep ($20–$60) represent significantly more affordable alternatives. More details: How to Help Patients Save Money on Clenpiq.

Tools and Resources for Your Practice

Several resources can help your practice navigate Clenpiq availability challenges:

• Medfinder for Providers: Real-time pharmacy stock search. Help patients find which pharmacies near them have Clenpiq in stock. Can be integrated into your pre-procedure workflow.
• Ferring Pharmaceuticals (1-888-FERRING): For questions about manufacturing status and supply.
• FDA Drug Shortage Database: Monitor official shortage listings at accessdata.fda.gov.
• Clenpiq.com: Patient-facing dosing assistant and manufacturer coupon download.

Looking Ahead

Several trends will likely affect Clenpiq availability in the coming years:

• No generic on the horizon: No generic version of Clenpiq has been publicly announced, meaning the single-source dynamic will continue.
• Growing colonoscopy volume: With screening now recommended starting at age 45, demand for bowel preps will continue to rise.
• Expanding low-volume prep market: Newer entrants like Suflave provide additional low-volume options, which may partially ease pressure on Clenpiq supply.

For practices that rely heavily on Clenpiq, maintaining flexible prep protocols with pre-identified alternatives remains the most effective strategy for avoiding procedure cancellations.

Final Thoughts

Clenpiq is not in an official shortage, but real-world availability continues to challenge practices and patients. Proactive prescribing, early Rx submission, flexible backup protocols, and tools like Medfinder can minimize disruptions to your colonoscopy schedule. Ultimately, the goal is to ensure no patient delays screening because of a bowel prep access issue.

For patient-facing resources on this topic, consider sharing: Clenpiq Shortage Update: What Patients Need to Know.